MRC1 and glioblastoma: Furthermore, though MMR-proficient cells are approximately 100 fold more sensitive to SN1 type methylators than their MMR-deficient counterparts[9], MMR deficiency makes a minor contribution to clinical resistance in GBM patients[10], suggesting that there exist unrecognized mechanisms of resistance.